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Background: It has been widely demonstrated that the hedgehog pathway is strongly associated with basal cell
carcinoma of the skin (NBCCS). To assess potential DNA alterations related to keratocystic odontogenic tumors
(KCOTs), we sequenced smoothened (SMO) genes in 12 sporadic KCOTs.
Methods: Polymerase chain reaction (PCR), capillary electrophoresis and dideoxy chain-termination sequencing
were used to examine potential DNA alterations in sporadic KCOTs.
Results: Five alterations in SMO genes were detected. Four of these mutations consisted of two synonymous and
three missense mutations; two of which have not been reported to date (c.T776A, c.T1281G).
Conclusions: SMO genes may play an important role in the sonic hedgehog (SHH) pathway and could also be
responsible for generating KCOTs and NBCCS. However, their influence on SHH signaling remains to be elucidated.
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Odontogenic keratocyst (OKC) is an aggressive, cystic
jaw lesion with strong growth potential and a high
recurrence rate. In recent years, the World Health
Organization (WHO) revised its name to keratocystic
odontogenic tumor (KCOT). This reclassification is
based on its aggressive behavior and high recurrence
rate, emphasizing that KCOT is a benign tumor rather
than a cyst [1-3]. Although the great majority of kerato-
cysts occur in isolation as single, non-syndromic cysts,
they may also present as multiple cysts as a feature of the
nevoid basal cell carcinoma syndrome (Gorlin syndrome,
OMIM#109400) [4].
At present, there are many manuscripts that focus on
the relationship between KCOT and PTCH1 (patched)
gene mutations, demonstrating that PTCH1, the gene
responsible for NBCCS, may also play an important role
in sporadic KCOTs [5-8]. The PTCH1 gene is a tumor
suppressor gene located at 9q22.32 [9]. A study of 14* Correspondence: moleculecf@gmail.com; litiejun22@vip.sina.com
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unless otherwise stated.patients with NBCCS-associated KCOTs and 29 patients
with sporadic KCOTs indicated that mutations in trans-
membrane 2 (TM2) are closely related to the development
of sporadic KCOTs [5].
The hedgehog (HH) signaling pathway is a key regulator
of embryonic development, controlling both cellular pro-
liferation and cell fate. Binding of sonic hedgehog (SHH)
to its receptor, patched (PTCH1), is believed to relieve
normal inhibition by PTCH1 of smoothened (SMO), a
seven-span transmembrane protein with homology to a
G-protein-coupled receptor [10].
SMO is a tumor-related gene located at 7q32.3, con-
tains 12 exons spanning approximately 24 kb, and en-
codes a 787-amino-acid transmembrane glycoprotein
[11]. Its receptor is a G protein-coupled receptor that
interacts with Patched, an important part of the HH
signaling pathway during embryogenesis as well as adult-
hood [12,13]. The HH pathway has been demonstrated to
play an important role in different development-related
cancers [14-18], but the exact mechanism of action has
not yet been elucidated. The protein generated by
SMO is downstream of PTCH1; that is, the expression
of PTCH1 restrains the activation of SMO, and thereby
inhibits activation of the HH pathway [19-22]. Recent
studies have highlighted the therapeutic value of SMO. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[22,23]. SMO, the main activator of the HH pathway
may serve as a catalyst during the generation of cysts,
and therefore, genetic mutations of SMO are of great
importance.
Methods
Tumor samples and clinical background
Fourteen KCOT samples with a definite diagnosis were
acquired from clinical sources at Peking University
School of Stomatology, Oral and Maxillofacial Surgery
Department. Diagnoses were based on WHO classifica-
tion of tumors: pathology and genetics of tumors of the
head and neck [24]. All samples were from Chinese pa-
tients (eight males and six females). Ages varied from 10
to 58 years, with an average of 29.2 years. Experimental
protocols used in this study were reviewed and approved
by the Ethics Committee of the Peking University Health
Science Center (Peking, China). Informed consent was
obtained from all subjects.
DNA isolation and mutation analysis
Genomic DNAs from epithelial cells and interstitial cells
of tumors were isolated using a QIAamp DNA Mini kit
(Qiagen, Hilden, American) according to the manu-
facturer’s instructions. DNA was quantified using a
Nanodrop (Thermo Fischer, Wilmington, DE). SMO
(NM_005631.4) coding sequences were determined
using polymerase chain reaction (PCR) and 1% agarose
gel electrophoresis. Thirteen pairs of primers covering
the entire coding sequences and a few nucleotides into
the intron sequences on both ends of SMO are de-
scribed in Table 1. PCRs were performed on a PTC-100
(MJ Research, Watertown, MA, USA) in a final volumeTable 1 PCR conditions of SMO exons




1 391 GGGCTGCTGCTGCTGCTG GTCCCCGC
2 283 AAGAACTGTCCTGCCCAGATG CCACTGGA
3 305 AATAATTTGCCAAGCCAGCC CTTCTGATC
4 256 AGGGTCATGATCAGAAGGGTC AGTATGCA
5 302 CTGACTTCTGGGAACCTCCAG GACAGAAG
6 206 GTGGCGCAGGTATAGTGACTG GCCCTATA
7 175 GACTCCAGAGCCTTAGGACCC TCCCTATG
8 196 AAGCAGTTCTTGGACTGAGCC CCATCCAT
9 379 AGTTGGAAGCTGCAGTGGG CAAGGCTG
10 228 CTCTGGAAAGAATGGCATCG TTCCAAAT
11 215 AATGGCACTGACTATGGGAGG CCACTCTTC
12a 292 GAGCCAGGGCCCCAGGCTCGT ACGCTCCC
12b 315 AGTACCATTCCTCGACTGCCT GGTATTGGof 30 μL containing approximately 100-ng template
DNA, 200 μmol/L dNTPs, 0.2–0.4 μmol/L each primer,
1.25 U ExTaq polymerase (TaKaRa, Dalian, China), and
10X PCR buffer (50 mmol/L KCl, 10 mmol/L Tris–HCl,
pH 9.0, and 1.5 mmol/L MgCl2). Exon 1, exon 12a and
exon 12b of the SMO gene were amplified by a touch-
down (TD) PCR technique (Table 1). For example, TD
65-56°C was performed as follows: an initial denaturation
step at 95°C for 5 min, followed by 40 cycles at 94°C for
30 s, 30 s at an annealing temperature decreasing from
65°C to 56°C (decrease of 1°C each 2 cycles, 20 cycles at
55°C), 30 s at 72°C, and a final extension step at 72°C
for 10 min. The specificity of amplified products was
confirmed by 2% agarose gel electrophoresis. PCR
products were purified by Life Technologies (Applied
Biosystems, USA) and sequenced by an ABI 3730xl
DNA sequencer (Applied Biosystems, USA). Both forward
and reverse strands were sequenced. Any mutation de-
tected was confirmed using both forward and reverse
primers.
Statistical analysis
Experimental data were analyzed using the SPSS ver. 10.0
software and are presented as means ± standard deviation
(SD) using statistical methods such as a t-test, analysis of
bivariate correlation, etc. A P value <0.05 was considered
to indicate statistical significance. Results are representa-
tive of two independent experiments.
Results and discussion
Hedgehog (HH) signaling pathway
Hedgehog (HH) is a signal transduction pathway closely
related to cell growth and differentiation, and plays a vital




CCTCTCCAAAACT Sun et al., 2008 [25] TD60 ~ 50
CCCTGCCCTATAC Wang et al., 2013 [12] 63
ATGACCCTTCCC Wang et al., 2013 [12] 63
GTAGGGCAGAGCC Wang et al., 2013 [12] 63
GTGGGTTACTGGC Wang et al., 2013 [12] 63
GGAGCTAGCTGGG Wang et al., 2013 [12] 63
GCTAACTTGTCCC Wang et al., 2013 [12] 63
TGAATCTGCTGTC Wang et al., 2013 [12] 55
TGCTAGAGGCAG Wang et al., 2013 [12] 63
AATCTGTGTGCCC Wang et al., 2013 [12] 55
AGATCCTCTGGG Wang et al., 2013 [12] 63
TGTCGGCAAGAGT Sun et al., 2008 [25] TD65-56
TTCCTCTCTTTCC Sun et al., 2008 [25] TD65-56
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various developmental defects and/or tumors. Altered HH
signaling is implicated in the development of approxi-
mately 20-25% of all cancers, especially those of soft
tissues [26]. These findings also suggest that proteins
of the HH signaling pathway are predominantly located
within the epithelial components of glandular odontogenic
cysts (GOCs) and dentigerous cysts (DCs). Therefore, the
HH signaling pathway may play an important role in
the formation of epithelial lining [27]. The discovery of
oncogenic mutations in the HH and mitogen-activated
protein kinase (MAPK) pathways in over 80% of ame-
loblastomas, locally destructive odontogenic tumors of
the jaw, was reported in 2014 by genomic analysis of
archival material. Mutations in SMO are common in
ameloblastomas of the maxilla, whereas BRAF muta-
tions are predominant in tumors of the mandible [28].
In addition, SHH subgroup medulloblastomas are gen-
etically distinct in infants, children and adults [29].
Most meningiomas have simple genomes, with fewer
mutations, rearrangements and copy-number alter-
ations than reported in other adult tumors. However,
several meningiomas harbor more complex patterns of
copy-number changes and rearrangements, including
one tumor with chromothripsis. A subset of meningiomas
lacking NF2 alterations harbored recurrent oncogenic mu-
tations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu),
and exhibited immunohistochemical evidence of acti-
vation of these pathways [11]. In another study, SMO
mutations, which activate the SHH signaling pathway,
were identified in ~5% of non-NF2 mutant meningiomas.
Collectively, these findings identify distinct meningioma
subtypes [30]. Moreover, some findings provide a ra-
tionale to explore the use of SMO and BCL2 inhibitors
as adjuvant therapy for treatment of DLBCL of the GC
type [31]. The expression of SMO in NPC is generally
high, whereas expression of PTCH-1 is relatively low.
Downregulation of PTCH1 and upregulation of SMO
may cause abnormal activation of the HH signaling
pathway in NPC, albeit that the genesis and develop-
ment of NPC may be associated with abnormal activa-
tion of HH signaling [32]. The HH signaling pathway is
controlled by PTCH1 and SMO, which are located on
the target cell’s membrane. As the receptor of sonic
hedgehog (SHH), the PTCH1 gene (51 kb) encodes a
12-transmembrane-domain protein (total, 1,447 amino
acids). There are two homologous genes in humans,
PTCH2 and PTCH1, which negatively regulate SMO, a
G-protein-coupled receptor, through SHH. SMO belongs
to the G protein-coupled receptor FZ/SMO superfamily,
containing a field that crosses the cell membrane seven
times. Without a ligand (SHH), PTCH and SMO form
an inhibitory compound, restraining signal transduction
throughout the entire pathway. However, when SHH bindsto PTCH1, SMO escapes from the inhibition by PTCH1,
resulting in enhanced expression of downstream target
genes, including the GLI superfamily [33]. As shown by
numerous researchers, abnormal activation of the HH
signaling pathway is closely related to the development
of a variety of tumors, and both PTCH1 and SMO play
a critical role in this pathway.
The HH signaling cascade is highly conserved and
involved in the development of disease throughout
evolution. Nevertheless, compared with other pathways,
our mechanistic understanding of HH signal transduction
is remarkably incomplete. In the absence of ligand, the
HH receptor Patched (Ptc), represses the key signal
transducer Smoothened (Smo) through an unknown
mechanism. HH binding to Ptc alleviates this repression,
causing Smo redistribution to the plasma membrane,
phosphorylation and subsequent opening of the Smo cyto-
plasmic tail and Smo oligomerization. However, the order
and interdependence of these events are poorly under-
stood. We have mathematically modeled and simulated
Smo activation for two alternative modes of activation,
with Ptc primarily affecting either Smo localization or
phosphorylation. Here, we show that Smo localization
to the plasma membrane is sufficient for phosphorylation
of the cytoplasmic tail in the presence of Ptc. Using fluor-
escence cross-correlation spectroscopy (FCCS), we also
demonstrated that inactivation of Ptc by HH induces Smo
clustering irrespective of Smo phosphorylation. Our ob-
servations therefore support a model of HH signal trans-
duction whereby subcellular localization of Smo, and not
phosphorylation, is the primary target of Ptc function [31].
Several studies [34-36] have confirmed that the PTCH1
gene is a tumor suppressor; this suggests that its mutation
increases the likelihood of developing cancer, although
few reports regarding the relationship between SMO and
KCOT have been published.
SMO mutations
Coding variants of SMO were identified following our
analysis, and the mutations are listed in Table 2. The
four SMO mutations detected were distributed on five
exons (exons 2, 3, 5, 6, and 10), of which there were two
synonymous mutations and three missense mutations.
The first alteration was located at nucleotide position
776 of exon 2, a heterozygous mutation from T to A
(Figure 1A); this alteration has not yet been reported by
other researchers. We determined that 9 of 12 KCOT
patients have this alteration. After comparing the protein
amino acid sequences of human, rice, mouse, and Dros-
ophila (Figure 2), we concluded that this amino acid is
relatively conserved. Meanwhile, following Genomics
online software SIFT [37] (http://sift.jcvi.org/) analysis, we
concluded that the amino acid change results in a negative
and damaging effect on the protein (Provean Preduction:
Table 2 SMO mutations in 12 sporadic and 19 NBCCS-associated KCOTs







S* K1, K2, K4,K5, K6, K7,
K8, K10, K11
Exon 2 c.T776A p.Phe166Ile — — Missense Unknown
S K7 Exon 3 c.A862G p. = (194)Glu rs56334250 0.0266 Synonymous Polymorphism
S K4 Exon 5 c.T1281G p.Val334Gly — — Missense Unknown
S K2, K3, K4, K5, K6, K7,
K8, K9, K10, K11, K12
Exon 6 c.G1444C p. = (388)Gly rs2228617 0.2277 Synonymous Polymorphism
N* N1, N2, N3, N4, N5, N6,
N7, N8, N9, N10, N11,
N12, N13, N14, N15,
N16, N17, N18, N19,
Exon 6 c.G1444C p. = (388)Gly rs2228617 0.2277 Synonymous Polymorphism
S K1 Exon 10 c.G2049C p.Ser590Thr rs114406835 0.010 Missense Polymorphism
*S = sporadic, N = NBCCS-associated.
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analysis, we discovered that the amino acid is located in a
cysteine-rich domain (CRD) of the Smoothened receptor
(Smo) integral membrane protein. The CRD is one of the
key players in the HH signaling pathway, and is critical for
development, cell growth and migration, as well as stem
cell maintenance. The CRD of Smo is conserved in verte-
brates and can also be identified in invertebrates. The pre-
cise function of the CRD in Smo is unknown. Mutations
in the Drosophila CRD disrupt Smo activity in vivo, while
deletion of the CRD in mammalian cells does not appear
to affect Smo overexpression [38-40]. Therefore, we be-
lieve that this amino acid may tremendously impact devel-
opment, cell growth and migration, as well as stem cell
maintenance. It is important to note that the peak of this
alteration is different from mutations at other positions.
For example, the peak of A is relatively lower than T, but
not as high as half of T. According to a recent report [41],
this may be due to the heterogeneity of tumors in issues
we detected, indicating that some cells have mutated while
others remain unchanged.
The second alteration, a heterozygous mutation from
A to G, was located at nucleotide position 862 of exon 3
(Figure 1B) but does not result in an amino acid change
at p.G194. The third mutation (c.G1444C, with G/C
alleles) was identified in seven tumors (Figure 1C), but
does not result in an amino acid change at p.G388. One
interesting fact about this synonymous mutation is, with
the exception of one sporadic KCOT, all other samples
(including sporadic and NBCCS-associated) were iden-
tified with this mutation, of which 17 were homozygous
and 13 were heterozygous. The frequency of G reached
a high of 0.7581, which is far higher than the statistic re-
ported in the single-nucleotide polymorphism (SNP)
database curated by the National Centre for Biotechnol-
ogy Information (NCBI) and the 1000 Genomes Project
(minor allele frequency [MAF] = 0.2277). This mutationhas been reported in many other cell lines associated
with mesothelioma, such as MSTO-211H, NCI-H28,
JU77, LO68, NO36, ONE58, and STY51 [42]. Therefore,
it is highly likely that this mutation plays a significant
role in the occurrence of tumors. However, whether this
mutation is related to KCOTs should be determined.
One of the missense mutations (c.G2049C, with G/C
alleles), which has been reported previously, has un-
known functional implications (Figure 1D). This muta-
tion leads to an amino acid change at p.Ser590Thr; it is
important to note that both Val and Gly can be phos-
phorylated. Meanwhile, SIFT software analysis revealed
that an interactive mutation between these amino acids
is neutral and tolerated (Table 3). In fact, this altered
amino acid is located within the intracellular loops of
Smoothened, which may be critically related to down-
stream proteins, and subsequently impact the functioning
of SMO, thereby impacting activation of the HH signaling
pathway [43].
The missense mutation (c.T1281G, with T/C alleles)
has not been reported previously (Figure 1E). This mu-
tation leads to an amino acid change (p.Val334Gly) lo-
cated on the first extracellular loop of Smoothened,
which is closely associated with the function of SMO.
Functional studies on transmembrane regions are re-
stricted by technological conditions, but according to
the SIFT software (Table 3), mutation of this amino
acid leads to damaging changes in the protein; therefore,
we believe that this mutation strongly impacts disease
occurrence. Additional studies are required to determine
whether this mutation causes functional changes in the
SMO gene.
The mode of action between the SMO and PTCH
genes has yet to be elucidated, but recent studies have
shown that any missing gene in yeast will impose
pressure on the cell to compensate, thereby leading to add-
itional genetic mutations [44]. Most SMO gene mutations
Figure 1 SMO missense mutation in sporadic KCOTs. A. This
alternation at nucleotide position 776 of exon 2 is a heterozygous
mutation from T to A and causes the p.Phe166Ile mutation. B. This
alternation at nucleotide position 862 of exon 3 is a heterozygous
mutation from A to G. However, this nucleotide change does not
result in amino acid change (p. = (194) Glu). Minor allele frequency
(MAF) = 0.0266. C. This alternation at nucleotide position 1444 of
exon 6 was identified in seven tumors. Among 31 patients sequenced,
17 are homozygous and 13 are heterozygous at this site. This nucleotide
change does not result in an amino acid change (p. = (388) Gly).
MAF = 0.2277. D. This alternation at nucleotide position 2049 of
exon 10 is a heterozygous mutation from G to C and causes the p.
Ser590Thr mutation. E. This alternation at nucleotide position 1281
of exon 5 is a heterozygous mutation from T to C and causes the
p.Val334Gly mutation.
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synonymous mutations, while frameshift and nonsense
mutations have not been detected. Therefore, we believe
that the SMO gene mutation may serve as a driving
force in patients with KCOTs. To compensate for the
defects caused by the SMO mutation, PTCH1 causes
the same signaling pathway to mutate, leading to muta-
tion(s) in the PTCH gene. This conjecture needs further
work to confirm. In most cases, people believe that
tumor growth is driven by the “latest” cancer cell subsets
because they carry most cancer mutations. However,
many mutations exist at a low frequency, suggesting that
tumors contain many subclones the relationships among
which are still unclear. A recent report examining the het-
erogeneity of breast cancer [41] showed that stem cells in
breast epithelia could differentiate into luminal and basal
cells, which constitute the epithelia. Some also believe that
breast neoplasms induced through Wnt1 overexpressionFigure 2 Conserved amino acids in human, rice, mouse, and
Drosophila. Amino acid sequences between human, rice, mouse,
and Drosophila are similar (t), indicating that amino acid residues are
relatively conserved at the mutation site detected (c.T776A).
Table 3 PROVEAN human protein batch result
Variation Protein sequence change PROVEAN prediction Sift prediction




1 NP_005622.1 166 F I −5.385 Deleterious 0.002 Damaging
2 NP_005622.1 334 V G −5.063 Deleterious 0.003 Damaging
3 NP_005622.1 590 S T −1.487 Neutral 0.219 Tolerated
Changes at amino acids 166 and 344 cause a deleterious alteration and a damaging result. The change at amino acid position 590 is relatively neutral and
tolerated by the protein.
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tween two cell types, which is driven by signaling mole-
cules, and its short distance, maintains co-existence of
two types of pedigree. Only luminal cells can produce
Wnt1, whereas basal cells rely on this protein to prolifer-
ate. Wnt1 induces the Hras gene in basal cells of breast
neoplasms, which may contain a mutation that drives
cancer progression, but this mutation has not yet been
detected in cancerous cells in the lumen. There is co-
operation between basal and luminal cell clones; this
cooperation is necessary for Wnt1 to drive two types of
cells in tumors. In addition, KCOTs occur during the
early stages of dental epithelial formation, during which
dental lamina and its residential, epithelium and stroma
interact with others during growth, subsequently inducing
differentiation. Therefore, we hypothesize that mutation
of some genes in the subcutaneous interstitial tissue may
impose pressure on epithelial genes to compensate for the
defect, and that the SMO mutation may play a critical role
in this process. However, additional studies are needed for
confirmation.
As we know, the hedgehog signaling pathway is being
suggested to be a drug target for cancer therapy for its
activation in human cancers [45-47]. Therefore, we think
the two newly identified SMO mutations deserve to be
further investigated for their therapeutic application in
cancer treatment.
Conclusions
Following the analysis of SMO gene mutations and com-
bining our results with similar studies, we conclude that
SMO plays an important role in the HH signaling pathway
and may be responsible for the development of KCOTs
and NBCCS. However, further research focusing on
the mechanism of their influence on the SHH signaling
pathway is required.
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